Novozymes A/S
CSE:NZYM B
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
346.4
419.5
|
| Price Target |
|
We'll email you a reminder when the closing price reaches DKK.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Novozymes A/S
Novozymes A/S
Other Liabilities
Novozymes A/S
Other Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Novozymes A/S
CSE:NZYM B
|
Other Liabilities
kr252m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
N/A
|
|
|
Chr Hansen Holding A/S
CSE:CHR
|
Other Liabilities
€50.1m
|
CAGR 3-Years
-34%
|
CAGR 5-Years
9%
|
CAGR 10-Years
6%
|
|
|
P
|
Photocat A/S
STO:PCAT
|
Other Liabilities
kr5.4m
|
CAGR 3-Years
15%
|
CAGR 5-Years
32%
|
CAGR 10-Years
N/A
|
|
Novozymes A/S
Glance View
Novozymes A/S is a global leader in biotechnology, focusing on the production of enzymes and microorganisms that enhance industrial processes. Founded in 1925 and based in Denmark, the company has consistently leveraged its deep scientific expertise to innovate solutions across various sectors, including agriculture, bioenergy, and food & beverage. By developing sustainable alternatives to traditional chemical processes, Novozymes not only improves efficiency for its clients but also helps minimize environmental impact. As industries continue to shift towards greener practices, Novozymes stands at the forefront of this transition, positioning itself as a pivotal player committed to driving sustainable development. For investors, Novozymes represents a compelling opportunity in a growing market driven by increasing awareness of sustainability and resource efficiency. The company boasts a diverse portfolio of products and a strong track record of profitability, sustained by its continuous investment in research and development. With a robust customer base spanning across more than 30 industries, Novozymes is well-equipped to capitalize on the expanding demand for bio-based solutions. Investors can find confidence in Novozymes' strategic focus on innovation and its ability to adapt to the evolving landscape of global sustainability goals, making it a strong candidate for those looking to invest in a future-oriented enterprise.
See Also
What is Novozymes A/S's Other Liabilities?
Other Liabilities
252m
DKK
Based on the financial report for Dec 31, 2023, Novozymes A/S's Other Liabilities amounts to 252m DKK.
What is Novozymes A/S's Other Liabilities growth rate?
Other Liabilities CAGR 5Y
-8%
Over the last year, the Other Liabilities growth was -80%. The average annual Other Liabilities growth rates for Novozymes A/S have been -2% over the past three years , -8% over the past five years .
You don't have any saved screeners yet
